AuthorisedHuman Pharmacology (Phase I)- OtherInterventional

A multi-part study to investigate MTX325 in healthy volunteers and patients with Parkinson's Disease

This study is exploring a new medicine, MTX325, in its very first stages of testing. It's designed to understand how the medicine behaves in the human body, first in healthy volunteers, and then in people who have Parkinson's disease. The main goal at this early phase is to check if MTX325 is safe and well-tolerated. Researchers will also be looking at how the body handles the medicine, for example, how much of it gets absorbed and how long it stays in the system. This type of early study is crucial to decide if a new medicine has the potential to help people with Parkinson's in the future.

At a glance

Status

Authorised

Phase

Human Pharmacology (Phase I)- Other

Sponsor

Mission Therapeutics Limited

Enrolment target

Start

18 May 2026

Parkinson's Disease

What is this study about?

You might have heard about clinical trials, which are research studies that test new medicines or treatments. This particular study is looking into a new medicine called MTX325. It's a very early stage of research, often called 'Phase 1' or 'Human Pharmacology'. This means the main aim is to understand whether MTX325 is safe for people to take and how it acts in the body.

The study will involve two groups of people. First, healthy volunteers will take MTX325. This helps researchers understand how the medicine works in a body without Parkinson's. If it seems safe and well-tolerated, the study will then include people who have Parkinson's disease. For them, researchers will continue to check safety and how the medicine works in their bodies, which might be different because of their condition.

Ultimately, the information gathered from this study is vital. It helps scientists decide if MTX325 is promising enough to continue testing in larger studies, which would then explore if it could effectively treat or manage Parkinson's symptoms. Every new medicine goes through this careful step-by-step process to ensure it's both safe and potentially helpful for patients.

Key takeaways

This is an early-stage study (Phase 1) looking at a new medicine called MTX325.
It aims to check the safety of MTX325 in healthy people and those with Parkinson's disease.
The study also wants to understand how the body handles this new medicine.
Participation involves regular clinic visits, medical checks, and taking the study medicine.
You can potentially contribute to future treatments for Parkinson's disease.
You can withdraw from the study at any time.

Who may be eligible?

To join any clinical study, there are certain requirements called 'eligibility criteria'. These typically include things like your age, overall health, and any other medical conditions you might have. These rules are put in place to ensure the safety of everyone taking part and to make sure the study results are clear and accurate.

For this study, both men and women aged 18 years and older are being considered. If you are interested in taking part, you would need to be either a healthy volunteer or someone who has been diagnosed with Parkinson's disease. There will be specific medical checks to make sure you fit the study's requirements.

It's important to remember that meeting the basic age and condition requirement doesn't automatically mean you can join. The research team will conduct a thorough assessment to see if you meet all the detailed criteria, which might include things like your other medications, and any other health conditions you may have.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Am I at least 18 years old?
Do I have a diagnosis of Parkinson's disease, or am I a healthy adult?
Am I able to attend regular clinic appointments?
Am I willing to take a new, experimental medicine?
Do I have any other serious health conditions that might prevent me from joining?

Answer every question to see your result.

What does participation involve?

If you decide to take part in this study, you will likely have a screening visit first. This is where the study team will carry out medical checks, review your health history, and explain the study in detail to make sure you're suitable.

Once enrolled, you would receive the study medicine, MTX325, as directed by the research team. You would also need to attend several scheduled visits to the study clinic. These visits typically involve physical examinations, blood tests, and other assessments to monitor your health and how the medicine is affecting you. There will also be check-ups to make sure you are not experiencing any unexpected side effects.

The total length of your participation, including the number of visits and the duration of medication, will be fully explained to you by the study team. They will also inform you about any follow-up appointments after you stop taking the medicine. All of these details will be clearly outlined before you agree to take part.

Potential risks and benefits

Taking part in a clinical study means there are potential benefits and potential risks. A potential benefit could be contributing to medical research that might one day lead to new treatments for Parkinson's disease. You would also receive close medical attention and monitoring throughout your participation. However, because MTX325 is a new medicine, there might be side effects that are not yet fully known. These could range from mild discomfort to more serious reactions. You will be given a document called an 'informed consent form' that lists all known and potential risks. It's important to remember that you are free to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (3)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

—
Unverified
Germany
—
Unverified
Netherlands
—
Unverified
France

Common questions

What is Parkinson's disease?

Parkinson's disease is a condition that affects the brain and can cause problems with movement, such as shaking, stiffness, and difficulty with balance.

What does 'Phase 1' study mean?

Phase 1 is the first stage of testing a new medicine in people. The main goals are to check if it's safe, what dose can be given, and how the body handles it.

Will I get better if I join this study?

Because this is an early-stage study, its main focus is on safety, not on treating the disease. There's no guarantee that MTX325 will improve your symptoms, but it's an important step in research.

How long will I be in the study?

The exact length of time you'd be involved will be explained by the study team during your first visit. It varies for each study.

Who funds this research?

Clinical trials are often funded by pharmaceutical companies, government organisations, or medical charities, but this specific information isn't provided here.